Elanco Animal Health- Units ( Purchase Contract & Senior Amortizing Note) EBIT

The latest EBIT for ELAT is $410M as of June 2026. That compares with $2B in the prior-year period — down 80.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Elanco Animal Health- Units ( Purchase Contract & Senior Amortizing Note)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ELAT's EBIT moved from $2B to $410M — a 80.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Elanco Animal Health- Units ( Purchase Contract & Senior Amortizing Note)'s operating scale or balance-sheet position.

Against Healthcare companies, ELAT currently prints $410M for EBIT, while the sector average sits near $110B. That is roughly 99.6% below the sector mean. Large gaps often invite a closer look at Elanco Animal Health- Units ( Purchase Contract & Senior Amortizing Note)'s growth, margins, and balance sheet.

A EBIT figure of $410M for ELAT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ELAT's EBIT ($410M), review year-over-year change from $2B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.